Breaking News, Collaborations & Alliances

Keapstone Therapeutics and Sygnature Discovery Collaborate

Will work to discover new therapies for Parkinson’s and Motor Neuron Disease

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Keapstone Therapeutics, a new biotech formed by the University of Sheffield and Parkinson’s UK to develop new drugs for Parkinson’s and other neurodegenerative diseases, and Sygnature Discovery, a UK-based drug discovery service provider, will collaborate to discover new treatments for Parkinson’s and Motor Neuron Disease (MND). Keapstone Therapeutics will build on research undertaken at the Sheffield Institute for Translational Neuroscience (SITraN) and an international collaboration with th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters